Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 102

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 102
---
ability and biological activity of liposomal ARBs in combination
with standard anticancer agents. While exploratory in nature and not designed to demonstrate definitive clinical efficacy, the results
lend scientific rationale for further investigation of Nano-Candesartan as a combination therapy candidate.

<div align='center'>65</div>

Key findings of pre-clinical results obtained
by us and third parties:

| - | Passive targeting. PEGylated                                                             
 nano-liposomes can exploit the enhanced permeability and retention (EPR) effect allowing 
 for passive targeting of tumors, without the need for specific ligands or receptors.     |

| - | Selective release. Specially                                                                         
 engineered liposomes can release ARBs selectively within tumors, minimizing systemic effects         
 on blood pressure while achieving TME normalization. The nano-ARB liposomal specific characteristics 
 might trigger the release of ARBs in response to the acidic or proteolytic environment of            
 the TME.                                                                                             |

| - | Proof-of-concept                                                                                                                   
 blood pressure effect studies conducted in mice by Prof. Barenholz’s team: the PEGylated nanoparticle-based ARB formulation        
 was compared to Valsartan. While Valsartan caused a reduction in mean blood pressure (MBP) within two hours of administration, the 
 nanoparticle-based ARB at comparable doses showed no measurable effect on MBP, supporting the underlying hypothesis regarding its  
 targeted delivery and reduced systemic impact (Fig 13).                                                                            |

| ● | In                                                                                          
 vitro assay for drug release in tumors was developed and was found to correlate the release 
 in the presence of tumors.                                                                  |

| ● | Lead                                                                                           
 formulations of valsartan and candesartan liposomes were selected based on having high loading 
 efficiency (low % of free drug), in vitro slow release in serum and more rapid release in      
 medium relevant to tumors.                                                                     |

| ● | The                                                                                        
 effect of valsartan liposomes in vivo on mice Blood Pressure (BP) was tested and compared  
 to similar dose of free valsartan. The study showed that indeed the free drug lowered mice 
 but the liposomal drug did not affect it. Fig 13                                           |

| ● | Initial                                                                                       
 studies with candesartan liposomes (25% HPCD formulation) showed no reduction in MBP, similar 
 to the results obtained for valsartan formulations. Fig.13                                    |

FIG.13 Mouse blood pressure (mmHg) after free valsart